Overview

ACVBP Plus Rituximab in Patients Aged From 18 to 59 Years With High-risk Diffuse Large B-cell Lymphoma

Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
This study is a multicentric trial evaluating the efficacy of R-ACVBP in patients aged 18 to 59 years with high risk diffuse large B-cell lymphoma
Phase:
Phase 2
Details
Lead Sponsor:
Lymphoma Study Association
Treatments:
Cyclophosphamide
Doxorubicin
Liposomal doxorubicin
Rituximab